- Disease: Post-COVID-19
- Study type: Randomised Clinical Trial, Adaptive Platform Trial, Treatment
- Study type descriptors: Interventional
- Objective: To assess the long-term effects of imatinib and infliximab, used during acute hospitalisation due to COVID-19-infection, on long-COVID symptoms and quality of life using questionnaires at six months, one and two years post-discharge
- Number of participants enrolled: Enrollment data not available
- Study enrolling from to
- Study includes follow-up for 2 years
Study Data
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Intensive care unit
- SARS-CoV-2
- Post-COVID-19
- Pharmacological intervention
- Monoclonal antibodies
- Immunomodulator
- Antineoplastic agent
- Imatinib
- Infliximab
External Links
Other information
Funders/Sponsors:
- Clinical Urology and Epidemiology Working Group
The information was provided with the aid of the study investigators
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to